Prohibit certain actions re: reimbursing 340B covered entities
Ohio HB 276 restricts reimbursement practices for 340B drug pricing program participants, affecting how safety-net healthcare providers can recoup medication costs.
Ohio HB 276 restricts reimbursement practices for 340B drug pricing program participants, affecting how safety-net healthcare providers can recoup medication costs.
HB 276 would restrict certain reimbursement practices related to the federal 340B drug pricing program, which allows covered entities (hospitals, clinics, and other healthcare providers serving vulnerable populations) to purchase medications at discounted prices. The bill appears designed to prevent specific financial arrangements or actions that currently occur around how these entities are reimbursed for 340B drugs, though the exact prohibited actions require review of the bill's full text.
The 340B program is a $50+ billion annual benefit intended to stretch limited healthcare dollars for safety-net providers. Changes to reimbursement rules directly affect whether these providers can afford to offer services to uninsured and underinsured patients. This legislation could either protect program integrity or potentially limit provider flexibility, depending on what specific practices are being prohibited.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.